Functional Proteomics to Dissect Signaling Pathways in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 157
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is one of the leading causes of death worldwide, underscoring the need for a better understanding of the mechanisms of cancer initiation, progression, and metastasis. Alterations in signaling pathways are hallmarks of cancer. These alterations lead to cell proliferation and metastasis, manifesting as the oncogenic phenotype.
Mass spectrometry-based omics technologies, including epigenomics, proteomics, and metabolomics, have become powerful tools to identify genomic and epigenetic variations, dissect signaling pathways, and stratify cancer subphenotypes. This Special Issue will collect studies that characterize cancer signaling pathways, phenotypes, and treatment effects using mass spectrometry and translate the molecular findings into cancer diagnosis and treatment methods. Specifically, we are interested in the following areas of research:
- Understanding cancer signaling pathways and protein–protein interactions with global proteomics or targeted mass spectrometry, such as selected reaction monitoring (PRM) or parallel reaction monitoring (PRM).
- Understanding how altered metabolism in cancer affects signaling pathways at the epigenetic and proteomic levels.
- Understanding the roles of protein posttranslational modifications, such as glycosylation, in cancer pathogenesis.
- Studies on the molecular mechanisms of cancer using integrated omics approaches, such as proteogenomics or chemical proteomics.
- Discovering biomarkers for cancer diagnosis and prognosis and the efficacy of cancer treatment using omics approaches.
Dr. Yingxin Zhao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
